middle.news
Nyrada Advances Xolatryp Trial with No Safety Concerns, Expands Dose Testing
8:56am on Monday 16th of June, 2025 AEST
•
Biotechnology
Read Story
Nyrada Advances Xolatryp Trial with No Safety Concerns, Expands Dose Testing
8:56am on Monday 16th of June, 2025 AEST
Key Points
No safety signals or dose-limiting toxicities reported in first four cohorts
Safety Review Committee approves progression to fifth cohort
Phase I trial protocol amended to include six cohorts with higher doses and longer infusion times
Preclinical studies show significant neuroprotective and cardioprotective effects
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE